2023
DOI: 10.1093/nar/gkad818
|View full text |Cite
|
Sign up to set email alerts
|

VARIDT 3.0: the phenotypic and regulatory variability of drug transporter

Jiayi Yin,
Zhen Chen,
Nanxin You
et al.

Abstract: The phenotypic and regulatory variability of drug transporter (DT) are vital for the understanding of drug responses, drug-drug interactions, multidrug resistances, and so on. The ADME property of a drug is collectively determined by multiple types of variability, such as: microbiota influence (MBI), transcriptional regulation (TSR), epigenetics regulation (EGR), exogenous modulation (EGM) and post-translational modification (PTM). However, no database has yet been available to comprehensively describe these v… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 18 publications
(1 citation statement)
references
References 94 publications
0
1
0
Order By: Relevance
“…Furthermore, the upcoming version of CyclicPepedia will predominantly focus on the data regarding cyclic peptide targets and their pharmacology properties. Pharmaceutical databases such as the Therapeutic Target Database [ 47 ], VARIDT [ 48 ], INTEDE [ 49 ], Comparative Toxicogenomics Database [ 50 ], TheMarker [ 51 ], and DrugMAP [ 52 ] will be explored for molecular interactions of cyclic peptides. Simultaneously, efforts will be made to enhance data quality and accuracy control, preventing the inclusion of duplicate or erroneous data.…”
Section: Discussionmentioning
confidence: 99%
“…Furthermore, the upcoming version of CyclicPepedia will predominantly focus on the data regarding cyclic peptide targets and their pharmacology properties. Pharmaceutical databases such as the Therapeutic Target Database [ 47 ], VARIDT [ 48 ], INTEDE [ 49 ], Comparative Toxicogenomics Database [ 50 ], TheMarker [ 51 ], and DrugMAP [ 52 ] will be explored for molecular interactions of cyclic peptides. Simultaneously, efforts will be made to enhance data quality and accuracy control, preventing the inclusion of duplicate or erroneous data.…”
Section: Discussionmentioning
confidence: 99%